#152628

HCT 116 BRCA2 -/- [42] Cell Line

Please Enter Your Email ID
Email ID

Cat. #152628

HCT 116 BRCA2 -/- [42] Cell Line

Cat. #: 152628

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Colon

Disease: Cancer

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Carlos Caldas

Institute: Cancer Research UK Cambridge Institute

Primary Citation: Xu et al. 2014. J Pathol. 234(3):386-97. PMID: 25043256

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: HCT 116 BRCA2 -/- [42] Cell Line
  • Alternate name: HCT 116 BRCA2(-/-) clone 42; HCT 116 BRCA2(-/-)
  • Cancer: Digestive/Gastrointestinal cancer
  • Cancers detailed: Colon Carcinoma
  • Research fields: Cancer;Drug development;Genetics
  • Tool sub type: Continuous
  • Parental cell: HCT 116 cell line
  • Clone: 42
  • Organism: Human
  • Tissue: Colon
  • Disease: Cancer
  • Model: Knock-Out
  • Model description: Targeted disruption of human BRCA2 by homologous recombination
  • Crispr: No
  • Conditional: No
  • Description: BRAC2 inherited mutations predispose carriers to various early onset cancers, including breast and ovarian. HCT116 BRCA2 -/- human colorectal carcinoma cell line was generated to study the role of BRCA2 in DNA repair, investigate the effects of BRCA2 mutations in a range of cancers, and identify additional functions of the BRCA2 gene. This homozygous knockout cell line shows phenotypes consistent with previous reports, including loss of Rad51 foci in the presence of double-strand breaks, chromosomal rearrangements and elevated sensitivity to the DNA-damaging agents phleomycin and Parp1 inhibitors
  • Application: Anticancer agents discovery and development; Cytotoxic agents' activity screening; Colony formation assay
  • Production details: Targeted disruption of the human BRCA2 locus in HCT116 cells by homologous recombination. The gene targeting construct was generated by using a recombinant adeno-associated virus (rAAV) system. The deletion was confirmed by Southern Blot and Western Blot using antibodies against the C-terminus of the BRCA2 protein. This cell line was noted as clone 42 by the originating laboratory
  • Biosafety level: 1
  • Additional notes: Clone 42 was generated at the same time as clone 46 cited in Xu et al. 2014. J Pathol. 234(3):386-97. PMID: 25043256. The originating laboratory have advised they observed no difference in culture phenotype between clone 42 and clone 46.
  • Recommended controls: HCT116 parental line
  • Cellosaurus id: CVCL_AS10

Target Details

  • Target: BRCA2 (BReast CAncer gene 2)
  • Target background: BRCA2 is a human tumor suppressor gene found in all humans. The primary role of its protein is in HR-mediated DNA damage repair

Applications

  • Application: Anticancer agents discovery and development; Cytotoxic agents' activity screening; Colony formation assay
  • Application notes: Clone 42 was generated at the same time as clone 46 cited in Xu et al., 2014. J Pathol. 2014 Nov;234(3):386-97. The originating laboratory have advised they observed no difference in culture phenotype between clone 42 and clone 46.

Handling

  • Format: Frozen
  • Volume: 1 ml
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes
  • Characterisation tests: BRCA2 deletion was confirmed by Southern Blot and Western Blot using antibodies against the C-terminus of the BRCA2 protein

Related Tools

  • Related tools: "HCT 116 BRCA2 -/- 46 Cell Line

References

  • Xu et al. 2014. J Pathol. 234(3):386-97. PMID: 25043256